Dossier · Private startup · 1 independent source
Binah.ai
Last updated: Jul 31, 2026
Binah.ai provides an AI-powered, video-based health-data platform that estimates vital signs and other wellness indicators from smartphone, tablet, laptop, and other camera streams, with optional continuous sensor workflows. It sells the capability primarily as an SDK and integration layer for healthcare, insurance, wellness, and related enterprise applications.
Visit WebsiteCompany Overview
Binah.ai's core product is a software-based physiological sensing platform. Its remote photoplethysmography (rPPG) pipeline analyzes subtle facial color changes captured by an ordinary camera and combines signal processing, computer vision, machine learning, and deep learning to estimate measures such as heart rate, respiration rate, oxygen saturation, heart-rate variability, stress-related indicators, and blood pressure. The company also presents additional bloodless blood-test and cardiovascular-risk features, while labeling at least some of those capabilities as under research. Its SDK is designed to run on consumer devices and, according to the company's product material, can perform inference on the device without requiring an internet connection. That architecture can reduce hardware, logistics, and cloud-data exposure, but it makes performance dependent on camera quality, lighting, user positioning, motion, and the quality of the company's calibration and validation data.
The commercial proposition is an enterprise data layer rather than a consumer diagnosis app. Binah.ai positions its integrations for telehealth intake, remote patient monitoring, primary and preventive care, insurance underwriting and engagement, corporate wellness, elder care, virtual trials, and in-car or device-embedded wellness experiences. The strongest buyer case is for organizations that already control a digital workflow and want a low-friction physiological check without issuing a cuff, wearable, or other dedicated device. The company has also publicized integrations and collaborations in wellness and insurance contexts, including a Polar continuous-monitoring relationship and an OSIM wellness-chair application. These are useful commercialization signals, but public-facing examples do not establish recurring revenue, conversion rates, clinical outcomes, or the scale of any customer deployment.
The competitive field includes specialist camera-based measurement companies such as NuraLogix and Lifelight, wearable or sensor-led monitoring providers such as Aktiia and Masimo, and broader digital-health platforms such as Biofourmis and TytoCare. Binah.ai's claimed differentiation is the combination of software-only spot checks, optional continuous checks, broad device accessibility, SDK distribution, and edge-oriented processing. That can create integration value when a customer wants to add measurements to an existing app or workflow, but it is not an unassailable technical moat: rPPG methods are an active research and product area, platform vendors can bundle adjacent capabilities, and customers may prefer validated hardware when measurement error has financial or clinical consequences. The company's ISO 13485:2016 certification for design and development of noninvasive vital-sign measurement software is a positive quality-system signal, not proof that every advertised indicator is clinically validated or cleared for every intended use.
Binah.ai has credible but bounded dual-use relevance. The underlying capability could support non-diagnostic readiness screening, emergency or disaster triage support, remote workforce health checks, and other situations where rapidly collecting basic physiological context is more practical than distributing hardware. It may also be relevant to security and resilience organizations that need low-touch intake across dispersed personnel or populations. No public evidence reviewed here establishes defense customers, government contracts, or mission-grade deployment, so the strategic case should remain an adjacency thesis. Before treating the system as suitable for operational or medical decision-making, diligence should test performance across skin tones, ages, devices, lighting conditions, motion, illness states, spoofing attempts, offline operation, cybersecurity, data retention, and escalation procedures. The company is best characterized as a mid-stage independent digital-health startup with meaningful technical and channel potential, but with material evidence, regulatory, and enterprise-execution questions still open.
Dual-Use Assessment
Binah.ai's camera-based physiological sensing can plausibly support civilian and security-adjacent screening, triage, readiness checks, and distributed workforce monitoring where dedicated devices are impractical. The dual-use case is credible at the collection and prioritization layer, but public evidence does not show defense customers, government contracts, or validation in mission environments; it should not be treated as a diagnostic or operational substitute without additional testing.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
Binah.ai remains a credible strategic-priority signal for a dual-use and deep-tech database because it addresses a real deployment bottleneck: collecting basic physiological context through software on devices that users already possess. Its SDK-led enterprise model, named healthcare and insurance use cases, current product activity, and ISO 13485 quality-system history support a plausible path to embedded distribution. This is not an investment recommendation. The central diligence questions are whether accuracy generalizes beyond controlled demonstrations, which indicators are actually cleared or commercially supported, whether integrations produce repeatable revenue, and whether the company has sufficient resources to sustain regulatory, clinical, security, and enterprise-support obligations after a 2020 Series B.
Strategic Value to U.S.-Israel Alliance
Binah.ai could add physiological signal density to existing telehealth, insurance, wellness, and connected-device channels without requiring each end user to receive dedicated hardware. That is strategically useful for resilience and security-adjacent workflows involving dispersed people, rapid intake, or constrained logistics. The value is greatest as an edge collection and prioritization component surrounded by human review, governance, and escalation controls. It is less compelling as a standalone defense sensor or autonomous medical-decision system because public evidence does not establish mission deployment, adversarial robustness, or universal clinical validity.
Key Technologies
- Remote photoplethysmography (rPPG) from smartphone, tablet, laptop, and embedded camera streams
- Computer vision, facial-region tracking, and signal-quality assessment
- Motion and environmental-noise handling for contactless physiological inference
- Machine-learning and deep-learning estimation of vital signs and digital biomarkers
- On-device or edge-oriented inference designed to reduce cloud dependency and data exposure
- SDK and API integration for spot checks, with optional continuous PPG sensor workflows
- ISO 13485-oriented software quality and medical-device development processes
Use Cases & Applications
- Telehealth pre-visit intake and remote patient monitoring augmentation
- Insurance wellness engagement, underwriting support, and dynamic risk-screening workflows
- Primary-care, preventive-care, and elder-care check-ins using existing consumer devices
- Virtual-trial screening, longitudinal biomarker collection, and participant adherence support
- Corporate wellness and workforce stress or fatigue trend monitoring
- Wellness features embedded in vehicles, furniture, fitness products, or consumer applications
- Emergency-response or disaster-relief triage support where distributing sensors is difficult
- Security- or resilience-adjacent readiness screening for dispersed personnel, subject to validation
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work; the research methodology documents how evidence is graded, what counts as an independent source, and why some profiles are excluded from search indexing.
This record lists 6 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- binah.ai Public source used for profile verification.
- binah.ai Public source used for profile verification.
- binah.ai Public source used for profile verification.
- binah.ai Public source used for profile verification.
- prweb.com Public source used for profile verification.
- LinkedIn company page Public source used for profile verification.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.